Sanam Loghavi: Relapse Patterns in NPM1-Mutated AML After Venetoclax-Based Therapy
Sanam Loghavi, Associate Professor of Pathology at MD Anderson Cancer Center, Medical Director of ECOG-ACRIN Leukemia Bank, and Editor in Chief of Image Bank at the American Society of Hematology, shared a post on X about a paper she co-authored with colleagues published in the American Journal of Hematology:
“We report the incidence of NPM1-wildtype relapses in patients treated with VEN-based frontline treatment in AML.
Overall, the absolute number of relapses in NPM1 AML after VEN is low
The fraction of NPM1-wildtype relapses is high with the high intensity of chemo backbone added to VEN.
NPM1 wildtype relapses occur later and often have MR mutations. And ALL (8/8) had a different flow immunophenotype compared to the original AML.
We proposed that these were ‘new’ AMLs, that arose from a common preleukemic (CH) precursor, but that the original NPM1-mutated AML was ‘cured’.”
Title: Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies
Authors: Wei-Ying Jen, Sanam Loghavi, Alexandre Bazinet, Alex Bataller, Ian Bouligny, Naval G. Daver, Ghayas C. Issa, Naszrin Arani, Emmanuel Almanza Huante, Abhishek Maiti, Guillermo Montalban-Bravo, Gautam Borthakur, Nicholas J. Short, Sherry Pierce, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Courtney D. DiNardo, Tapan M. Kadia
You can read the Full Article in the American Journal of Hematology.
More posts featuring Sanam Loghavi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023